Clinical Trial Update: Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib combined with irinotecan as a second-line treatment for small cell lung cancer; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Small Cell Lung Cancer, Angiogenesis | Phase 2 | Status: UNKNOWN